Antipsychotic agents and lithium
Upcoming SlideShare
Loading in...5
×
 

Antipsychotic agents and lithium

on

  • 2,689 views

The underlined words are hyperlinks; please click on them to see the whole presentation.

The underlined words are hyperlinks; please click on them to see the whole presentation.

Please tell me what you think about my slides, you can write to: mh_farjoo@yahoo.com

Statistics

Views

Total Views
2,689
Slideshare-icon Views on SlideShare
2,245
Embed Views
444

Actions

Likes
2
Downloads
155
Comments
0

2 Embeds 444

http://www.onestudentnursetoanother.com 441
http://study.myllps.com 3

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Antipsychotic agents and lithium Antipsychotic agents and lithium Presentation Transcript

    • Antipsychotic Agents & Lithium By M.H.Farjoo M.D. , Ph.D.Shahid Beheshti University of Medical Science
    • Antipsychotic Agents & Lithium Introduction  Mania Dopamine Hypothesis  Lithium Dopaminergic Systems  Mechanism of Action  Clinical Application Antipsychotic Drugs  Adverse Effects Classification  Special Issues Clinical Application  Newer drugs Adverse Effects  Drug Pictures Overdose Drug Choice
    • DepressionPsychosis Mania
    • Introduction to Schizophrenia Schizophrenia remains a scientific mystery and a personal disaster. Many patients show little response and virtually none show a complete response. The psychosis produced by phencyclidine (PCP) has been used as a model for schizophrenia. This drug is an antagonist of the NMDA glutamate receptor.
    • Dopamine Hypothesis  Most antipsychotic drugs strongly block dopamine receptors (D2) in the CNS.  Increase in dopaminergic activity aggravates schizophrenia.  Dopamine receptors are increased in the brains of schizophrenics who have not been treated.  Dopamine receptor density in both treated and untreated schizophrenics is more than nonschizophrenics.  Successful treatment of schizophrenics changes the amount of homovanillic acid, a metabolite of dopamine.M.H.Farjoo
    • Dopamine Hypothesis cont,d  The dopamine hypothesis is far from complete.  Antipsychotic drugs are only partially effective for most and ineffective for some patients.  Antagonists of NMDA (phencyclidine) produce more schizophrenic symptoms than do dopamine agonists.  New antipsychotics (clozapine, olanzapine, and aripiprazole) have much less effect on D2 receptors.  Most of the newer "atypical" antipsychotics have significant inhibitory effect on the 5-HT2 receptor.M.H.Farjoo
    • Dopamine receptor typeD1 family D1 & D5 ↑cAMP Dilates renal blood vesselsD2 family D2 , D3 & D4 ↓ cAMP Modulates transmitter release
    • Dopaminergic Systems Mesolimbic-mesocortical pathway: most closely related to behavior. Nigrostriatal pathway: it is involved in the coordination of voluntary movement. Tuberoinfundibular system: physiologically inhibits prolactin secretion. Medullary-periventricular pathway: may be involved in eating behavior. Incertohypothalamic pathway: not well defined
    • Antipsychotic Drugs The antipsychotics block D2 receptors in the mesolimbic- mesocortical systems. The therapeutic potency of antipsychotics does not correlate with their affinity for the D1 receptor but with D2 affinity. The antagonism of dopamine in the nigrostriatal system explains the parkinsonism produced by these drugs. The hyperprolactinemia is caused by blockade of dopamines tonic inhibitory effect on prolactin release from the pituitary.
    • Classification  Phenothiazines Chlorpromazine  Thioxanthene Thioridazine Thiothixene Trifluoprazine  Butyrophenone Perphenazine Haloperidol Fluphenazine  Newer atypical drugs Droperidol Pimozide Clozapine Loxapine Olanzapine RisperidoneM.H.Farjoo Aripiprazole
    • Clinical Application  Schizophrenia.  Manic phase in bipolar disorders.  In combination with a TCA or SSRI in clearly depressed psychotic patient.  As antiemetics (except thioridazine).M.H.Farjoo
    • Adverse Effects  Pseudodepression Due to drug induced akinesia  Extrapyramidal reactions. by antiparkinson drugs Treated  Autonomic blocking effects.  Hyperprolactinemia Can induce infertility  Toxic-confusional states Very high doses of drugs  Agranulocytosis that have antimuscarinic Seen with clozapine actionsM.H.Farjoo
    • Extrapyramidal System The extrapyramidal system is part of the motor system involved in the coordination of movement. It is called "extrapyramidal" to distinguish it from the motor tracts traveling through the "pyramids" of the medulla. The pyramidal pathways directly innervate motor neurons of the spinal cord. The extrapyramidal system modulates and regulates anterior horn cells.
    • Extrapyramidal Reactions Extrapyramidal toxicity is associated with high D2 potency. Extrapyramidal reactions include:  Parkinsons syndrome: (diminished activity)  Tardive dyskinesia: (increased activity) eg: choreo- athetoid movements.  Akathisia (uncontrollable restlessness)  Dystonia, eg: spastic retrocollis or torticollis)
    • Extrapyramidal Reactions Cont,d Tardive dyskinesia, is the most important unwanted effect of antipsychotic drugs. It is caused by a relative cholinergic deficiency secondary to supersensitivity of dopamine receptors The first step is to reduce the antipsychotic or switch to one of the newer agents. The second step is to eliminate all drugs with central anticholinergic action, particularly antiparkinsonism drugs and TCAs.
    • Adverse Effects cont,d  Ocular complications  Arrhythmia Deposit in cornea & lens (chlorpromazine) Thioridazine overdose can cause  Neuroleptic malignant syndrome in retina & browning of vision Deposit sudden (thioridazine) death  Can be fatal  in patients extremely sensitive to the extrapyramidal effects of antipsychotics  Muscle rigidity (lead pipe rigidity)  Very high fever Confused with  Leukocytosis infection  BP & PR instability  Elevated creatine kinase isozymes  Treated by antiparkinson drugs & diazepamM.H.Farjoo
    • Overdose  Rarely is fatal, Except thioridazine.  Gastric lavage should be done even if several hours have elapsed.  Manifested by:  Miosis  Hypotension Responds to fluid  Hypothermia replacement  Drowsiness  Agitation  ComaM.H.Farjoo
    • Drug Choice The low cost of the older drugs contributes to their widespread use despite their clear side effects. Newer antipsychotics (clozapine, risperidone, and olanzapine) show superiority over haloperidol. The lower side effect of the newer agents and low risk of tardive dyskinesia makes them first line of treatment.
    • Drug Choice Cont,d The best guide for selecting a drug for an individual patient is the patients past responses to drugs. Within the older group, the trend has been toward the high-potency drugs (haloperidol). Clozapine is limited to those who have failed to respond to conventional antipsychotic drugs.
    • Drug Choice Cont,d The agranulocytosis and seizures associated with this drug prevent more widespread use. Risperidones lower side effects have caused its widespread use. Patients who fail to respond to one drug may respond to another; so several drugs should be tried.
    • Lithium Mechanism of Action  Preponderance of catecholamine related activity is thought to be present.  The drug may decrease norepinephrine and dopamine turnover.  Post receptor effects.  The prophylactic use of lithium can prevent both mania and depression.M.H.Farjoo
    • Effect of lithium on the IP3 and DAG second-messenger system. The schematic diagram shows thesynaptic membrane of a neuron. (PIP2,phosphatidylinositol-4,5-bisphosphate; PLC,phospholipase-C; G, coupling protein; EFFECTS,activation of protein kinase C, mobilization ofintracellular Ca2+, etc.) Lithium, by inhibiting therecycling of inositol substrates, may cause depletion ofthe second-messenger source PIP2 and thereforereduce the release of IP3 and DAG. Lithium may alsoact by other mechanisms.
    • Lithium Clinical Application  Bipolar Affective Disorder.  Schizoaffective disorders (a mixture of schizophrenia and depression).  Adjunct to antidepressants in major depression.M.H.Farjoo
    • Lithium Adverse Effects  Tremor is very common and occurs in therapeutic doses.  Neurologic abnormalities: ataxia, aphasia and confusion.  Appearance of any new neurologic abnormality is a clear indication for stopping treatment and TDM.  Decreases thyroid function.  Antagonizes ADH, resulting in nephrogenic diabetes insipidus.  The bradycardia-tachycardia ("sick sinus") syndrome is a definite contraindication.M.H.Farjoo
    • Lithium Special Issues  Lithium serum concentration after delivery can rise to toxic concentrations  Lithium is found in breast milk, up to ½ that of serumM.H.Farjoo
    • Newer drugs  Valproic acid (valproate):  Overall, it shows efficacy equivalent to that of lithium during the early weeks of treatment.  Valproic acid is effective in some patients who have failed to respond to lithium.  The mode of action of is unclear.  Valproic acid is becoming recognized as a first- line treatment for mania.M.H.Farjoo
    • Newer drugs (Cont’d)  Carbamazepine:  The mode of action of is unclear.  Carbamazepine has been considered to be a reasonable alternative to lithium when the latter is less than optimally efficacious.  Carbamazepine may be used to treat acute mania and also for prophylactic therapy.  Overdoses are a major emergency and should be managed like overdoses of TCAs.M.H.Farjoo
    • Summary In English
    • Thank you Any question?
    • Structural formulas of some older antipsychotic drugs: phenothiazines, thioxanthenes, and butyrophenones.
    • Structural formulas of some newer antipsychotic drugs
    • Antipsychotic drugs: Relation of chemical structure to potency and toxicities. D2/5-HT2A Clinical Extrapyramidal Sedative Hypotensive Chemical Class Drug Ratio1 Potency Toxicity Action ActionsPhenothiazines Aliphatic Chlorpromazine High Low Medium High High Piperazine Fluphenazine High High High Low Very lowThioxanthene Thiothixene Very high High Medium Medium MediumButyrophenone Haloperidol Medium High Very high Low Very lowDibenzodiazepine Clozapine Very low Medium Very low Low MediumBenzisoxazole Risperidone Very low High Low2 Low LowThienobenzodiazepine Olanzapine Low High Very low Medium Low Low toDibenzothiazepine Quetiapine Low Low Very low Medium mediumDihydroindolone Ziprasidone Low Medium Very low Low Very lowDihydrocarbostyril Aripiprazole Medium High Very low Very low Low1Ratio of affinity for D2 receptors to affinity for 5-HT2A receptors.2At dosages below 8 mg/d.
    • Adverse pharmacologic effects of antipsychotic drugs. Type Manifestations MechanismAutonomic Loss of accommodation, drynervous mouth, difficulty urinating, Muscarinic cholinoceptor blockadesystem constipation Orthostatic hypotension, Alpha adrenoceptor blockade impotence, failure to ejaculateCentral Parkinsons syndrome, akathisia,nervous Dopamine receptor blockade dystoniassystem Supersensitivity of dopamine Tardive dyskinesia receptors Toxic-confusional state Muscarinic blockadeEndocrine Amenorrhea-galactorrhea, Dopamine receptor blockadesystem infertility, impotence resulting in hyperprolactinemia Possibly combined H1 and 5-HT2Other Weight gain blockade
    • Dose relationships of antipsychotics. Minimum Effective Usual Range of Therapeutic Dose Daily Doses (mg) (mg)Chlorpromazine (Thorazine) 100 100-1000Thioridazine (Mellaril) 100 100-800Trifluoperazine (Stelazine) 5 5-60Perphenazine (Trilafon) 10 8-64Fluphenazine (Permitil, Prolixin) 2 2-60Thiothixene (Navane) 2 2-120Haloperidol (Haldol) 2 2-60Loxapine (Loxitane) 10 20-160Molindone (Lidone, Moban) 10 20-200Clozapine (Clozaril) 50 300-600Olanzapine (Zyprexa) 5 10-30Quetiapine (Seroquel) 150 150-800Risperidone (Risperdal) 4 4-16Ziprasidone (Zeldox) 40 80-160Aripiprazole (Abilify) 10 10-30